	JC03 Rec'd PCT/PTO 0.5 APR 2009								
FORM (REV. 0	PTO-1: 01-2003	US DEPARTMENT OF COMMERCE	ATTORNEY'S DOCKET NUMBER 122536						
	D	ANSMITTAL LETTER THE ESIGNATED/ELECTED OF DICERNING A FILING UNI	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/522,333						
	RNAT	IONAL APPLICATION NO. 8/02299	PRIORITY DATE CLAIMED July 25, 2002						
PAR'	TITLE OF INVENTION PARTICLES WHICH ARE SURFACE COATED WITH HYALURONAN OR ONE OF THE DERIVATIVES THEREOF AND THE USE OF SAME AS BIOLOGICAL VECTORS FOR ACTIVE SUBSTANCES								
	APPLICANTS FOR DO/EQ/US Edith DELLACHERIE et al.								
Appli	Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
1.		This is a FIRST submission of item	s concerning a filing under 35 U.S.	.C. 371.					
2.	\boxtimes	This is a SECOND or SUBSEQUE	NT submission of items concerning	g a filing under 35 U.S.C. 371.					
3.		This is an express request to begin items (5), (6), (9) and (21) indicated	national examination procedures (d below.	35 U.S.C. 371(f)). The submission must include					
4.		The US has been elected (Article 3	11).						
5.		A copy of the International Applicat	ion as filed (35 U.S.C. 371(c)(2))						
		a. is attached hereto (required	only if not communicated by the Ir	ternational Bureau).					
		b. \square has been communicated by	the International Bureau.						
		c. \square is not required, as the applic	cation was filed in the United States	s Receiving Office (RO/US).					
6.		An English language translation of	the International Application as file	d (35 U.S.C. 371(c)(2))					
		 a. is attached hereto. 							
		b. has been previously submitted	ted under 35 U.S.C. 154(d)(4).						
		c.	n was filed in English.						
7.		Amendments to the claims of the Ir	nternational Application under PCT	Article 19 (35 U.S.C. 371(c)(3))					
		a. are attached hereto (require	ed only if not communicated by the	International Bureau).					
		b. have been communicated by the International Bureau.							
		c. have not been made; hower	ver, the time limit for making such a	amendments has NOT expired.					
		d. have not been made and wi	ill not be made.						
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).							
10.		An English language translation of (35 U.S.C. 371(c)(5)).	the annexes of the International Pr	reliminary Examination Report under PCT Article 36					
ltem:	s 11 1	to 20 below concern document(s)	or information included:						
11.	\boxtimes	An Information Disclosure Stateme	ent under 37 CFR 1.97 and 1.98.						
12.		An assignment document for recor	rding. A separate cover sheet in co	ompliance with 37 CFR 3.28 and 3.31 is included.					
13.		A preliminary amendment.							
14.		An Application Data Sheet under 3	7 CFR 1.76.						
15.		A substitute specification.							
16.		A power of attorney and/or change	of address letter.						
17.		A computer-readable form of the s	equence listing in accordance with	PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.					
18.		A second copy of the published int							
19.		**	uage translation of the internationa	application under 35 U.S.C. 154(d)(4).					
20.		Other items or information:							

				_				
u.s. APPLICATION NO. (if known, 10/522,333	QRNEY'S DOCKET NUMBER 2536							
21. The following fees	s are submitted:			CALCULATIONS	PTO USE ONLY			
BASIC NATIONAL FEE (3	7 CFR 1.492(a)):		\$ 300.00	\$				
SEARCH FEE (37 CFR 1.4	92(b)(1)-(3)):			\$				
International search fee (37	CFR 1.445(a)(2)) p	aid to USPTO as ISA	\$ 100.00					
International search report the search fee is paid	provided to USPTO	t which \$ 400.00						
All situations not provided f			\$ 500.00					
EXAMINATION FEE (37 C	FR 1.492(c)(1)-(2)):			\$				
International preliminary ex IPEA and favorable as to n for all claims presented in t	ovelty, inventive step he application enteri							
All situations not provided f	or above		\$ 200.00					
Surcharge of \$130.00 for fu earliest claimed priority dat TOTAL PAGES OF	e (37 CFR 1.492(e))	declaration later than 3	0 months from the	\$				
APPLICATION OVER 100 (- 100)	÷ 50	= †	'x 250 =	\$				
tround up to next integer								
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$				
TOTAL CLAIMS	- 20	=	x 50.00 =	\$				
INDEPENDENT CLAIMS	- 3	=	x 200.00 =	\$				
MULTIPLE DEPENDENT			+ 360.00 =	\$				
Applicant claims small reduced by 1/2.		TOTAL OF ABOVE OF CFR 1.27. The fees		\$				
reduced by 72.			SUBTOTAL =	\$				
Processing fee of \$130.00 the earliest claimed priority	for furnishing the En date (37 CFR 1.492	glish translation later th		\$				
			NATIONAL FEE =	\$				
Fee for recording the enclo accompanied by an approp	sed assignment (37	ignment must be	\$					
accompanies by an approp	mate cover ancet (or		ES ENCLOSED =	\$				
				Amount to be				
- 7				refunded:	\$			
a.	In the amount of \$	to cover the abo	ove fees is enclosed.	charged:	3			
	my Deposit Account	No in the amou		the above fees. A du	plicate copy of this			
Deposit Accour	nt No. <u>15-0461</u> . A dı	ized to charge any add plicate copy of this she	eet is enclosed.					
d. Feés are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a potition to revive (37 CFR 1.137(a) or (b))								
must be filed and granted to restore the application to pending status. SEND ALL CORRESPONDENCE TO:								
OLIFF & BERRIDG				r /_				
Customer Numbe	r: 25944		NAME: WILL REGISTRATIO	am P. Berridge ON NUMBER: 30,0	24			
Date <u>April 5, 2005</u>			NAME: Jesse		20			
REGISTRATION NUMBER: 53,839								





PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

XH

In re the Application of

Edith DELLACHERIE et al.

Application No.: 10/522,333

Filed: January 25, 2005

Docket No.: 122536

For: PARTICLES WHICH ARE SURFACE COATED WITH HYALURONAN OR ONE OF THE DERIVATIVES THEREOF AND THE USE OF SAME AS BIOLOGICAL VECTORS

FOR ACTIVE SUBSTANCES

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefform.

- 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- 2. Relevance of the references 1-2 are discussed in the present specification.

Respectfully submitted

William P. Berridge Registration No. 30,024

Jesse 6. Collier Registration No. 53.839

WPB:JOC/mps Date: April 5, 2005

OLIFF & BERRIDGE, PLC P.O. Box 19928 Alexandria, Virginia 22320 Telephone: (703) 836-6400 DEPOSIT ACCOUNT USE AUTHORIZATION Please grant any extension necessary for entry; Charge any fee due to our Deposit Account No. 15-0461

Sheet	1	of	1	

Form PTO-1449 (REV. 8-83)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 122536			APPLICATION NO. 10/522,333			
INFORMATION DISCLOSURE STATEMENT										
(Use several sheets if necessary)				APPLICANTS Edith DELLACHERIE et al.						
				FILING DATE January 25, 2005				GROUP		
U.S. PATENT DOCUMENTS										
EXAMINER INITIAL		DOCUMENT NUMBER	r	DATE		N.	АМЕ		CLASS	SUB CLASS
		FOREIG		TOUT DO	CUMENTS	,				
		DOCUMENT NUMBER		DATE	COMENTS		JNTRY		CLASS	SUB CLASS
/J.P./	1	FR 2 794 763	12/15/2000		FRANCE	:				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)										
/J.P./	2	GURNEY et al., "Development of Bio Dev. and Ind. Pharm., vol. 7, no. 1, pp	evelopment of Biodegradable and Injectable Latices for Controlled Release of Potent Drugs						s," Drug	
	-							-		
	_									
EXAMINER	EXAMINER /Jeffrey Palenik/ DATE CONSIDERED 11/27/2007									
		citation considered, whether or not en ance and not considered. Include copy of						w line th	hrough citat	ion if not in